FIELD: biotechnology.
SUBSTANCE: group of inventions relates to the field of immunology, in particular to the BCMA antibody, its antigen-binding fragment and their medical application. Disclosed are an anti-BCMA antibody or an antigen-binding fragment thereof, a pharmaceutical composition, a cytotoxic conjugate and use thereof as a medicinal agent for treating or detecting and diagnosing BCMA-mediated diseases or conditions. Antibody has high affinity, high specificity, low immunogenicity, high biological activity, significant anti-tumour action and enhanced endocytosis.
EFFECT: present invention can find further application in therapy of various BCMA-mediated diseases or conditions.
35 cl, 10 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, WHICH SPECIFICALLY BINDS TO BCMA, AND USE THEREOF | 2022 |
|
RU2820350C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
